Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.
Blanchet B, Xu-Vuilard A, Jouinot A, Puisset F, Combarel D, Huillard O, Le Louedec F, Thomas F, Teixeira M, Flippot R, Mourey L, Albiges L, Pudlarz T, Joly C, Tournigand C, Chauvin J, Puszkiel A, Chatelut E, Decleves X, Vidal M, Goldwasser F, Oudard S, Medioni J, Vano YA. Blanchet B, et al. Among authors: chatelut e. Br J Cancer. 2024 Apr;130(6):961-969. doi: 10.1038/s41416-024-02585-y. Epub 2024 Jan 25. Br J Cancer. 2024. PMID: 38272963
Clinical pharmacodynamic factors in docetaxel toxicity.
Puisset F, Alexandre J, Treluyer JM, Raoul V, Roché H, Goldwasser F, Chatelut E. Puisset F, et al. Among authors: chatelut e. Br J Cancer. 2007 Aug 6;97(3):290-6. doi: 10.1038/sj.bjc.6603872. Epub 2007 Jun 26. Br J Cancer. 2007. PMID: 17595656 Free PMC article. Clinical Trial.
Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.
Puszkiel A, White-Koning M, Dupin N, Kramkimel N, Thomas-Schoemann A, Noé G, Chapuis N, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Among authors: chatelut e. Pharmacol Res. 2016 Nov;113(Pt A):709-718. doi: 10.1016/j.phrs.2016.06.032. Epub 2016 Jul 1. Pharmacol Res. 2016. PMID: 27378568
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto MN, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B. Puszkiel A, et al. Among authors: chatelut e. Clin Pharmacokinet. 2019 Apr;58(4):451-467. doi: 10.1007/s40262-018-0703-0. Clin Pharmacokinet. 2019. PMID: 30094711 Review.
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F. Le Louedec F, et al. Among authors: chatelut e. Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13. Br J Clin Pharmacol. 2019. PMID: 30811063 Free PMC article. Clinical Trial.
239 results